## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.0% in mid entry zone (4.0-10.0%), top 7% cross-sectional ranking. Short-term MRS_5 (3.1%) confirms momentum alignment. Momentum building (+0.8% 5-day). Outperforming sector by 8.3%. Caution: overbought RSI (70).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($79.17)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy a**
- Source: PharmiWeb.com | 20251203T220744 | Bullish | Relevance: 100%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, a research collaboration aimed at transforming personalized radiation therapy and cancer care. The initiative integrates imaging, AI, and patient monitoring, focusing on four key pillars: automation, predictive oncology, multi-modal therapies, and outpatient monitoring. This collaboration seeks to enhance clinical outcomes, reduce clinician burnout, and accelerate innovation in radiation oncology.

**2. GE HealthCare and Mayo Clinic unveil GEMINI-RT, a bold research collaboration in radiation therapy and advanced cancer care**
- Source: Mayo Clinic News Network | 20251203T183915 | Bullish | Relevance: 100%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, a research collaboration aimed at transforming personalized radiation therapy and cancer care. The initiative focuses on integrating imaging, AI, and patient monitoring across the cancer care continuum, with pillars including automation, predictive oncology, multi-modal therapies, and outpatient monitoring. This collaboration builds on previous research efforts and seeks to make personalized radiation therapy more accessible and effective.

**3. GE HealthCare (Nasdaq: GEHC), Mayo Clinic unveil GEMINI-RT to advance AI-guided radiation therapy**
- Source: Stock Titan | 20251203T130000 | Bullish | Relevance: 100%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, a research collaboration aimed at transforming personalized radiation therapy for cancer care using AI and advanced imaging. The initiative focuses on automation, predictive oncology, multi-modal therapies, and connected care to improve patient outcomes and reduce clinician burnout. This builds on a prior strategic radiology research alliance, leveraging Mayo Clinic's clinical expertise and GE HealthCare's technological innovation.

**4. University of Rochester Medical Center and GE HealthCare form seven-year Care Alliance to build advanced capabilities across system**
- Source: Business Wire | 20251203T080600 | Bullish | Relevance: 100%
- The University of Rochester Medical Center (URMC) and GE HealthCare have announced a seven-year Care Alliance to enhance advanced capabilities across URMC's facilities in upstate New York. This multi-year collaboration aims to establish a center of excellence in Imaging Sciences, introduce diagnostic tracer production for molecular imaging, and standardize patient monitoring throughout the UR Medicine health system. The initiative is expected to improve patient care, operational efficiency, and access to advanced diagnostic and therapeutic technologies.

**5. GE HealthCare Technologies prices $1.25 billion in new notes offering**
- Source: Investing.com | 20251202T170500 | Somewhat-Bullish | Relevance: 100%
- GE HealthCare Technologies announced the pricing of a $1.25 billion underwritten public offering of senior notes, consisting of $600 million at 4.150% due December 15, 2028, and $650 million at 4.950% due December 15, 2035. Despite the new debt, the company maintains a reasonable debt-to-equity ratio of 1.08 and an Altman Z-Score of 2.66, indicating moderate financial stability. This comes alongside other recent news, including a quarterly cash dividend and regulatory applications for new imaging technologies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.50 elevated, pricing in significant growth expectations. Forward P/E 16.9x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.2B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.50 |
| Forward P/E | 16.9 |
| Current P/E | 18.4 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 3.1% confirms short-term momentum alignment. AM_20 at 10.1% shows strong absolute momentum above own 20MA. Outperforming sector by 8.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.90), confirming momentum. RSI overbought at 70, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.04% (CS: 93) | Strong |
| RSI_14 | 70.5 | Overbought |
| MACD Histogram | 0.90 | Bullish |
| vs SMA20 | 1.101x | Above |
| vs SMA50 | 1.110x | Above |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $83.59
- **Stop Loss:** $79.17 (5.3% risk)
- **Target:** $90.22 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 214
- **Position Value:** $17,888.26
- **Portfolio %:** 17.89%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*